Leerink Partnrs Expects Stronger Earnings for Inari Medical

Inari Medical, Inc. (NASDAQ:NARI) – Research analysts at Leerink Partnrs increased their Q4 2024 earnings per share estimates for Inari Medical in a research report issued on Monday, October 28th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings of $0.02 per share for the quarter, up from their previous estimate of ($0.07). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.75) per share. Leerink Partnrs also issued estimates for Inari Medical’s Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS and FY2025 earnings at $0.19 EPS.

Inari Medical (NASDAQ:NARI) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.25). Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%. The firm had revenue of $145.82 million for the quarter, compared to analysts’ expectations of $143.96 million.

Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus initiated coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective for the company. Deutsche Bank Aktiengesellschaft assumed coverage on Inari Medical in a research report on Friday, August 9th. They issued a “buy” rating and a $68.00 price target for the company. Wells Fargo & Company reduced their price objective on Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Leerink Partners began coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price objective for the company. Finally, Canaccord Genuity Group boosted their target price on Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $58.89.

Inari Medical Stock Performance

NARI stock opened at $48.40 on Thursday. The firm has a fifty day moving average price of $43.50 and a 200 day moving average price of $45.97. Inari Medical has a fifty-two week low of $36.73 and a fifty-two week high of $67.13. The firm has a market cap of $2.82 billion, a PE ratio of -36.48 and a beta of 1.00.

Insider Activity

In related news, CFO Mitch C. Hill sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $47.99, for a total value of $239,950.00. Following the transaction, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,619,004. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Inari Medical news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mitch C. Hill sold 5,000 shares of Inari Medical stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $47.99, for a total transaction of $239,950.00. Following the transaction, the chief financial officer now directly owns 179,600 shares in the company, valued at approximately $8,619,004. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 131,000 shares of company stock valued at $6,161,340. 10.60% of the stock is currently owned by company insiders.

Institutional Trading of Inari Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Motley Fool Asset Management LLC lifted its stake in shares of Inari Medical by 46.2% during the 1st quarter. Motley Fool Asset Management LLC now owns 64,677 shares of the company’s stock worth $3,103,000 after purchasing an additional 20,438 shares during the last quarter. Bamco Inc. NY lifted its position in shares of Inari Medical by 27.4% during the first quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock valued at $37,288,000 after buying an additional 167,000 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Inari Medical during the second quarter valued at about $2,145,000. Integral Health Asset Management LLC boosted its holdings in shares of Inari Medical by 100.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after buying an additional 200,000 shares in the last quarter. Finally, Maryland State Retirement & Pension System purchased a new position in shares of Inari Medical in the 1st quarter worth approximately $886,000. Institutional investors own 90.98% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.